3 407

Cited 20 times in

A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation

Authors
 S.J. Kim  ;  K.H. Huh  ;  D.-J. Han  ;  I.S. Moon  ;  S.-J. Kim  ;  Y.-L. Kim  ;  H.C. Kim  ;  S. Lee  ;  C.-M. Kang  ;  B.-H. Cho  ;  Y.S. Kim 
Citation
 TRANSPLANTATION PROCEEDINGS, Vol.41(5) : 1671-1674, 2009 
Journal Title
 TRANSPLANTATION PROCEEDINGS 
ISSN
 0041-1345 
Issue Date
2009
MeSH
Adult ; Creatinine/blood ; Drugs, Generic/therapeutic use ; Graft Rejection/epidemiology ; Humans ; Hypercholesterolemia/epidemiology ; Hypertriglyceridemia/epidemiology ; Immunosuppressive Agents/therapeutic use ; Kidney Transplantation/immunology* ; Middle Aged ; Pilot Projects ; Postoperative Complications/epidemiology ; Postoperative Complications/immunology ; Safety ; Tacrolimus/therapeutic use*
Abstract
OBJECTIVE: Tacrolimus has been shown to be an important immunosuppressive agent in organ and bone marrow transplantation. Previously, we reported that there were no statistically significant differences between the pharmacokinetic parameters of the oral formulation of generic tacrolimus (TacroBell) and the conventional formulation (Prograf). This study was designed to evaluate the efficacy and safety of oral capsules of TacroBell in de novo renal transplantation. METHODS: Ninety-six renal transplant recipients from 9 transplantation centers in South Korea were enrolled between November 2005 and July 2007. De novo renal recipients ranged from 19-65 years old. Ninety-four patients who underwent renal transplantation were administered study drug at least one time in the intent-to-treat (ITT) analysis. This phase 4 clinical trial was a 26-week, open-label, noncomparative, multicenter study. RESULTS: An acute rejection episode developed in 10/94 recipients (10.6%, 95% confidence interval, 4.4%-16.9%). There were no patient deaths during the study. The 6-month graft survival rate was 96.8%. CONCLUSION: Based on this study, treatment with TacroBell is considered to be efficient and safe after primary renal transplantation.
Full Text
http://www.sciencedirect.com/science/article/pii/S0041134509004333
DOI
10.1016/j.transproceed.2009.03.061
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Jin(김수진)
Kim, Yu Seun(김유선) ORCID logo https://orcid.org/0000-0002-5105-1567
Huh, Kyu Ha(허규하) ORCID logo https://orcid.org/0000-0003-1364-6989
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/104009
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse